What are the implications of device-detected subclinical atrial tachyarrhythmias?
Device-detected subclinical atrial tachyarrhythmias have implications for patient management and risk of stroke and other cardiovascular events. The European Heart Rhythm Association (EHRA) published a consensus document in 2017 outlining the definition, implications and management of these arrhythmias. The document was endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiología (SOLEACE). The document states that device-detected subclinical atrial tachyarrhythmias can lead to an increased risk of stroke, heart failure, and other cardiovascular events. As such, the document recommends that clinicians should consider the implications of these arrhythmias and discuss the evidence-based risk stratification and management options with the patient. In addition, the document recommends the use of anticoagulant therapy for certain high-risk subclinical atrial tachyarrhythmias.  